The Changing Face of Canadian Regulatory Compliance
If you are a regulatory professional in Canada, 2026 is a year you cannot afford to ignore. Health Canada is adopting the ICH E6(R3) guideline on April 1, 2026, and that means GCP re-training is mandatory for researchers and research teams across the country.
Canada’s regulatory framework for pharmaceuticals, biologics, and medical devices is governed by Health Canada under the Food and Drugs Act and its regulations. Canadian professionals must navigate clinical trial requirements under Part C, Division 5, pharmaceutical submissions like New Drug Submissions (NDS), and biologics licensing, all while aligning with ICH guidelines.
But here is the kicker. Canada’s close integration with the US market means that a strong understanding of FDA regulations is essential for many Canadian professionals working on global submissions. If you are handling submissions that cross borders, you need expertise in both Health Canada and FDA pathways.
Key Regulatory Frameworks for Canadian Professionals
Health Canada operates under the Food and Drugs Act and Regulations which provide overall legislative authority for drugs and devices. The Guidance for Industry on Product Monograph serves as the core document for prescription drug submissions. Health Canada has adopted ICH E6(R3) GCP effective April 1, 2026, setting ethical and scientific quality standards for clinical trials. For US submissions, professionals need to understand 21 CFR Parts 50, 56, 312, 314, 600, and 601. And ICH Guidelines across the E, M, Q, and S series provide international harmonisation for global drug development.
Canada’s active participation in ICH and its proximity to the US mean that professionals with expertise in both Health Canada and FDA pathways are highly valued. And with Health Canada’s implementation of ICH E6(R3) on April 1, 2026, staying current has never been more critical.
Our Health Canada-Aligned Regulatory Affairs Training Courses
All courses are self-paced, available online, and include 21 CFR Part 11 compliant certificates with verifiable IDs. These are accepted as documented training records during regulatory inspections.
Certified Regulatory Affairs Professional (CRAP)
Price: $799.00
Comprehensive certification covering the global pharmaceutical regulatory landscape. This program provides end-to-end knowledge of the drug development lifecycle with specific focus on FDA, EMA, and Health Canada requirements, as well as harmonization initiatives under ICH. It covers all major application types including IND, NDA, ANDA, and BLA, making it the ideal foundational program for Canadian professionals working on both domestic and international submissions.
This course is designed for Regulatory Affairs Professionals, Clinical Development Teams, CMC Specialists, and Quality Assurance Personnel. Access the full course here: Certified Regulatory Affairs Professional.
The Investigational New Drug (IND) Framework (Highly Applicable for Canada)
Price: $499.00
A comprehensive, end-to-end understanding of the IND framework as regulated by the US FDA. While US-centric, this knowledge is critical for Canadian sponsors and CROs conducting clinical trials in the US or submitting Clinical Trial Applications (CTAs) to Health Canada that reference US data. The course covers 21 CFR Part 312, safety reporting, and sponsor responsibilities.
This course targets Clinical Research Associates, Regulatory Affairs Specialists, Principal Investigators, and Sponsor or CRO personnel. Learn more: The Investigational New Drug Framework.
Mastering the NDA (Applicable for Canada)
Price: $499.00
This program covers the entire drug development and approval process, focusing on the preparation of a complete New Drug Application (NDA) organized into the five CTD modules. This training is essential for Canadian professionals involved in submitting NDSs to Health Canada, as the CTD format is the international standard used by both agencies.
This course is suited for Regulatory Affairs Specialists, Medical Writers, CMC Associates, and Clinical Research Associates. Explore the course: Mastering the NDA.
Biologics License Application (BLA) Certification Program (Applicable for Canada)
Price: $499.00
Provides comprehensive knowledge of the planning, preparation, and submission of BLAs to the FDA. This is crucial for Canadian biotech companies and professionals seeking to enter the US market with biological products. The course covers CMC, nonclinical and clinical data requirements, and FDA review processes.
This program is designed for Regulatory Affairs Professionals, CMC Scientists, Biotechnology Executives, and Quality Assurance Personnel. Find out more: Biologics License Application Certification Program.
Mastering the Orphan Drug NDA (Applicable for Canada)
Price: $499.00
Covers the entire orphan drug development and approval process, from rare disease discovery through NDA submission and maintenance of seven-year exclusivity. This is highly relevant for Canadian companies developing therapies for rare diseases and seeking designation from both the FDA and Health Canada.
This course targets Regulatory Affairs Specialists working in gene therapies and biologics, Clinical Research Associates, and Medical Writers. Enroll here: Mastering the Orphan Drug NDA.
ANDA Compliance and Regulatory Training (Applicable for Canada)
Price: $499.00
Provides an in-depth understanding of the regulatory requirements for preparing and submitting Abbreviated New Drug Applications (ANDAs) to the US FDA. This is vital for Canadian generic pharmaceutical companies looking to export to the US market.
This course is designed for Regulatory Affairs Professionals, Pharmaceutical Development Scientists, and Quality Assurance Managers. Access the course: ANDA Compliance and Regulatory Training.
Who Needs Regulatory Training in Canada?
Regulatory training is a critical requirement for all personnel involved in the research, development, and commercialization of drugs and biological products in Canada. Sponsors and CROs including commercial and non-commercial sponsors and Contract Research Organizations need this training. Regulatory Affairs professionals at all levels from Associates to Directors and Strategy Specialists require ongoing education. Clinical Operations teams including Clinical Research Associates, Clinical Trial Monitors, and Data Managers need regulatory knowledge. R&D and Manufacturing personnel such as Formulation Scientists, CMC Specialists, and Quality Assurance and Control staff must maintain documented training. Legal and Compliance professionals including Patent Attorneys, Compliance Officers, and Research Compliance Professionals also benefit from regulatory training.
Frequently Asked Questions
Is online regulatory training accepted by Health Canada?
Yes. Health Canada does not mandate a specific training delivery format. The key is that the training is documented, role-appropriate, and effective. Our 21 CFR Part 11 compliant certificates provide verifiable proof of training that is recognized during inspections.
Do you offer group discounts for Canadian companies?
Yes. We offer corporate and group enrollment options for teams of all sizes. Contact us for a custom quote.
How long do I have access to the course?
All courses include lifetime access, so you can study at your own pace on your own schedule.
Are the certificates verifiable?
Yes. Each certificate includes a unique verifiable ID that can be checked at gxptrainings.com/verify-certificate/.
Do Not Get Left Behind, ICH E6(R3) Is Coming
With Health Canada’s adoption of ICH E6(R3) taking effect April 1, 2026, Canadian regulatory professionals need to act now. Ensure your training is current, documented, and aligned with the latest standards. Visit GxP Trainings to explore our full range of regulatory affairs training courses designed specifically for Canadian professionals.
Authors
